rebates

A few readers have sent me messages and asked me to detail some basics of risk adjustment (RA) — how it works, its benefits, and its challenges — and the controversy surrounding risk adjustment data validation (RADV) in Medicare Advantage (MA) specifically. RA is a complex world, but here is my best effort to keep the overview simple and then move to the coming RADV conflagration. While not practiced in the employer world because of the penetration of self-insured funds under the Employee Retirement Income Security Act (ERISA, where the employer shoulders the entire burden of costs and insurers are not at risk), risk adjustment has become an important and common practice in MA, Medicaid managed care, and Exchange managed care. Quite simply, risk adjustment is critical to ensuring that health plans are compensated fairly to cover the costs of a given individual as well as the population as a

In my last blog, I gave you my healthcare year-in-review for 2023.  After that, as I always do each year, I play Nostradamus to prognosticate about what will happen in the next twelve months in the world of healthcare. Despite my Irish last name, I do have French blood (well, 50% French Canadien, so I count it). But I don’t claim to be an oracle or seer like our 16th century physician, apothecary, and astrologer friend. I do take a page from Nostradamus, though, in that my healthcare predictions for 2023 (not really prophecies) will be sometimes deliberately vague (they include a lot of mays, coulds, shoulds, and possibles) so as to amass a reasonable record for those tracking and putting together my forecasting report card for the history books. Here is hoping my crystal ball is clear and not cloudy, but don’t hold me to any of this; I am simply